Small caps to watch: Chemtrade and Minto Apartment REIT among stocks set to see active trading today

The article is a mixed small-cap earnings roundup led by Chemtrade, Cineplex, Cronos, Doman Building Materials, and Minto Apartment REIT. Chemtrade posted $503-million in revenue and kept 2026 Adjusted EBITDA guidance unchanged, while Cineplex missed revenue expectations at $291-million and reported a larger-than-expected loss; Doman beat on EPS and EBITDA, and Kneat rose more than 10% on strategic-review speculation. The piece also highlights a heavy slate of upcoming small-cap earnings over the next several weeks, with no broad market-level catalyst.

Analysis

The tape is rewarding names where execution is improving faster than the market can re-rate fundamentals, but the dispersion is widening. The cleanest signal is that balance-sheet quality and self-help are being priced more aggressively than top-line growth: that favors cash-generative small caps with visible capital returns, while leverage-sensitive consumer/real-asset names remain vulnerable if rates or inputs stay sticky. The group’s strong absolute performance also raises the bar for any miss — the next leg is likely to be driven more by guidance credibility and capital allocation than by reported quarterly beats.

Among the current movers, the strategic-review catalyst in software has asymmetric upside because the market is effectively paying for optionality before diligence cost becomes visible. That is usually good for the stock, but the second-order effect is that it can pull forward buyer interest across the fragmented Canadian small-cap tech space, especially where recurring revenue and governance clean-up are present. By contrast, entertainment and housing-linked materials look more exposed to “good headline, weaker earnings quality” reactions: they can rally on revenue recovery but still de-rate if losses, leases, or pricing pressure keep EBITDA-to-cash conversion subdued.

The contrarian setup is in the cyclicals with improving margins but still-depressed sentiment. Building materials and housing-adjacent names can keep compounding even if end markets stay soft, because the market tends to underwrite only volume recovery and misses margin durability from pricing discipline and cost resets. On the other side, the cannabis beat may not be durable enough to justify a rerate unless tax and international mix stay favorable for multiple quarters; that makes it more of a trading vehicle than a fundamental compounding story unless capital allocation improves materially.

Near term, the highest probability catalyst chain is this week’s earnings slate: any guidance raise from industrials, payments, or consumer defensives should help validate the idea that small-cap revisions are turning up. The main risk is that after a strong 12-month run, even modest misses get punished for multiple compression, so position sizing should favor pairs and optionality over outright beta.

Key Decisions for Investors

• Long KSI.TO on strategic-review optionality for the next 2-6 weeks; size for a takeover-style payoff, but cap downside with a tight thesis stop if no process milestones emerge.
• Long DBM.TO vs short a housing-sensitive peer basket into the next 1-2 quarters; thesis is margin durability and self-help can outperform even before housing turns.
• Short CGX.TO on any post-earnings strength over the next 1-3 weeks; the market is likely overvaluing recovery optics while underappreciating weak cash conversion and event-risk around governance/succession.
• Trade CRON as a momentum long only into the next earnings cycle, but take profits quickly on strength; the move is more vulnerable to mean reversion than a true multiple expansion absent sustained EBITDA durability.
• For the upcoming earnings window, use call spreads on names with clean balance sheets and operating leverage rather than outright longs; this is a market where revisions matter more than headline beats.